Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D iber/mezi Two multiple myeloma CELMODs are in registrational trials iberdomide • Synergistic in vitro activity with anti-CD38 mAb¹ • Properties enable combinability, enhanced anti-MM activity, and favorable tolerability Potential to establish iberdomide in combination with anti- CD38 mAb in earlier lines • mezigdomide Highly potent, optimized for rapid and maximal degradation of target proteins • Induces tumor cell death and responses needed to regain control in advanced disease • ⚫ Potential to establish mezigdomide-Pl triplet combination in later lines, post-lenalidomide and anti-CD38 mAb Asset (indication) Phase 1 Phase 2 mezigdomide (RRMM 2-4L) SUCCESSOR-12 mezigdomide (RRMM 2L+) SUCCESSOR-23 iberdomide (RRMM 2-3L) EXCALIBER-RRMM4 iberdomide (post-SCT maintenance) EXCALIBER-MAINTENANCE5 Phase 3 Projected Data Readout 2026 2026 2026 2029 1. Hansen JD, et al. J Med Chem. 2020 Jul 9;63(13):6648-6676. 2. NCT05519085; 3. NCT05552976; 4. NCT04975997; 5. NCT05827016 Ill Bristol Myers Squibb™ Not for Product Promotional Use 90 90

View entire presentation